Eikon Therapeutics appoints Ma. Fatima D. Francisco to Board as Class I director

Eikon Therapeutics, Inc.

Appointment effective June 15, 2026; serves until 2027 annual meeting.
Annual retainer of $50,000 paid quarterly; initial option for 85,937 shares at $8.96.
Option vests in 48 equal monthly installments subject to continued service.
Ms. Francisco will serve on the Compensation Committee of the Board.
No arrangements or related-person transactions with the Company disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ma. Fatima D. Francisco

Class I director

EIKN · Eikon Therapeutics, Inc.

Effective: 2026-06-15
Filed: June 10, 2026, 4:15 PM ET

the Board of Directors (the “Board”) of Eikon Therapeutics, Inc. (the “Company”) appointed Ma. Fatima D. Francisco to the Board as a Class I director, effective June 15, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ma. Fatima D. Francisco was appointed as Class I director at Eikon Therapeutics, Inc..

Action: appointed
Role: Class I director

Exact text from the filing

the Board of Directors (the “Board”) of Eikon Therapeutics, Inc. (the “Company”) appointed Ma. Fatima D. Francisco to the Board as a Class I director, effective June 15, 2026.

View on SEC.gov

Eikon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-265861

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.